Infinity Pharmaceuticals Company Profile (NASDAQ:INFI)

Analyst Ratings

Consensus Ratings for Infinity Pharmaceuticals (NASDAQ:INFI) (?)
Ratings Breakdown: 9 Hold Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $6.75 (301.79% upside)

Analysts' Ratings History for Infinity Pharmaceuticals (NASDAQ:INFI)
Show:
DateFirmActionRatingPrice TargetActions
6/28/2016FBR & CoReiterated RatingMarket Perform$2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/28/2016WedbushReiterated RatingNeutral$1.25View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016Jefferies GroupDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016William BlairDowngradeOutperform -> Market Perform$20.00 -> $2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016Wells Fargo & Co.DowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016Morgan StanleyDowngradeOverweight -> Equal WeightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016Royal Bank Of CanadaDowngradeOutperform -> Sector Perform$12.00 -> $2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016JPMorgan Chase & Co.DowngradeOverweight -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2015Stifel NicolausReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2015NomuraReiterated RatingNeutral -> Buy$17.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015Deutsche Bank AGInitiated CoverageBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/4/2014Credit Suisse Group AGUpgradeNeutral -> Outperform$20.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/3/2014Roth CapitalReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Infinity Pharmaceuticals (NASDAQ:INFI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/4/2016Q116($0.82)($0.82)$8.80 million$9.26 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2016Q415($0.72)($0.80)$18.26 million$9.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.63)$0.84$24.85 million$90.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($1.00)($0.78)$5.83 million$4.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($1.68)($1.91)$5.79 million$4.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015Q414($0.98)($0.83)$5.61 million$4.36 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314$0.30$2.03$141.40 million$160.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2014Q114($0.84)($0.78)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q1($0.83)($0.87)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2014Q413($0.87)($0.68)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013($0.75)($0.71)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.62)($0.68)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2012Q312($0.57)$0.52$13.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.91)($0.79)($0.85)
Q2 20164($1.02)($0.83)($0.92)
Q3 20164($0.89)($0.76)($0.83)
Q4 20164($1.04)$3.15$1.07
Q1 20171($0.14)($0.14)($0.14)
Q2 20171($0.14)($0.14)($0.14)
Q3 20171($0.14)($0.14)($0.14)
Q4 20171($0.14)($0.14)($0.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Infinity Pharmaceuticals (NASDAQ:INFI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Infinity Pharmaceuticals (NASDAQ:INFI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/25/2015Adelene Q PerkinsCEOSell5,000$10.93$54,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Vito J PalombellaInsiderSell4,737$10.97$51,964.89View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2015Adelene Q PerkinsCEOSell10,000$12.81$128,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2015Adelene Q PerkinsCEOSell10,000$12.18$121,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Adelene Q PerkinsCEOSell20,000$16.00$320,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2015Adelene Q PerkinsCEOSell20,000$14.83$296,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014Vito J PalombellaInsiderSell4,737$16.32$77,307.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2014Vito J PalombellaInsiderSell4,736$15.00$71,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2014Anthony B EvninDirectorSell112,451$13.56$1,524,835.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2014Vito J PalombellaInsiderSell9,472$15.39$145,774.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/27/2013Anthony B EvninDirectorSell163,864$14.82$2,428,464.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/13/2013Adelene PerkinsCEOSell45,000$20.72$932,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2013Vito J PalombellaInsiderSell23,150$18.53$428,969.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2012Christopher M LindblomInsiderSell13,885$25.73$357,261.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/7/2012Co BeaconMajor ShareholderBuy5,416,565$14.50$78,540,192.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Infinity Pharmaceuticals (NASDAQ:INFI)
DateHeadline
07/29/16 07:34 AMAbbVie Inc Earnings Call (Q2 2016)
07/26/16 04:19 PMINFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
07/26/16 07:36 AMPieris Pharmaceuticals Appoints Julian Adams, Ph.D., to Its Board of Directors
07/23/16 08:39 AMBiotech news that matter for investors: Infinity Pharmaceuticals ... - The Voice Registrar
07/22/16 07:36 AMInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) Updated Price Targets - FTSE News
07/20/16 09:00 PMInfinity Pharmaceuticals Inc. (INFI) Jumps 8.05% on July 20 - Equities.com
07/20/16 02:39 PMAnalyst's Noticeable Buzzers: DexCom, Inc. (NASDAQ:DXCM) , Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - Street Updates
07/20/16 02:39 PMTrading the Biotech News: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - The Voice Registrar
07/20/16 07:38 AMInfinity Pharmaceuticals, Inc. (NASDAQ:INFI): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/19/16 04:44 PMHeightened Volatility Spotted on Shares of: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - Engelwood Daily
07/19/16 04:44 PMBiotech Stocks To Put On Your Watch List: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), EPIRUS Biopharmaceuticals ... - The Voice Registrar
07/18/16 04:49 PMTrading Performance and Target Watch for Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - Press Telegraph
07/18/16 04:49 PMAre Analysts Bearish Infinity Pharmaceuticals Inc. (NASDAQ:INFI) After Last Week? - Consumer Eagle
07/18/16 04:49 PMStocks in Queue: Oracle Corporation (NYSE:ORCL), Infinity Pharmaceuticals Inc.(NASDAQ:INFI) - NYSE Journal (press release)
07/18/16 04:49 PMInfinity Pharmaceuticals Inc Stock Momentum Hits Weakness - CML News
07/18/16 12:54 PMETF’s with exposure to Infinity Pharmaceuticals, Inc. : July 18, 2016 -
07/15/16 03:42 PMIncreased Volatility Noted on Shares of: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - Engelwood Daily
07/14/16 08:09 AMAnalysts Rating updates about two Stocks: Valeant Pharmaceuticals International, Inc. (NYSE:VRX) , Infinity ... - Street Updates
07/13/16 05:01 PMDecibel Therapeutics Appoints Steven H. Holtzman as President and Chief Executive Officer
07/13/16 05:01 PMBiotech veteran Holtzman joins Decibel as CEO
07/12/16 04:54 PMInfinity Pharmaceuticals Inc versus XOMA Corporation Head to Head Compare - CML News
07/12/16 09:00 AMNow what? How biotechs deal with failure
07/11/16 04:43 PMStock Runners: Evoke Pharma, Inc. (NASDAQ:EVOK), Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), Cimarex Energy ... - KC Register
07/11/16 04:43 PMStock Volatility Focus for: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - Engelwood Daily
07/11/16 04:43 PMCompany Shares of Infinity Pharmaceuticals (NASDAQ:INFI) Rally 2.19% - TheFounders Daily
07/10/16 09:00 AMWill Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Surprise This Quarter? - Investor Newswire
07/10/16 09:00 AMInfinity Pharmaceuticals Inc. (INFI) Jumps 6.06% on July 08 - Equities.com
07/07/16 04:44 PMAnalyst's Overview of Two Stocks: Teva Pharmaceutical Industries Limited (NYSE:TEVA) , Infinity Pharmaceuticals, Inc ... - Street Updates
07/07/16 04:44 PMInfinity Pharmaceuticals, Inc. versus Osiris Therapeutics, Inc. Head to Head Compare - CML News
07/07/16 07:31 AMInfinity Pharmaceuticals Inc. (INFI) Drops 5.84% on July 05 - Equities.com
07/06/16 03:31 AMInfinis plc £350m 7% Senior Notes due 2019 Announcement of annual results for the year ended 31 March 2016 - [at noodls] - 25e53bbd-1453-432f-8a3a-028769918e21.pdf £350 million 7% Senior Notes due 2019 Annual Results Announcement Infinis plc (the "Issuer"), an indirectly wholly owned subsidiary of Infinis Energy ...
07/05/16 04:31 PMNASDAQ:INFI Stockholder Notice: Investigation of potential Wrongdoing at Infinity Pharmaceuticals Inc.
07/02/16 07:31 AMRecently Issued Stock Ratings For Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - Fiscal Standard
07/01/16 07:26 AMShort Term Price Target on Infinity Pharmaceuticals (INFI) - Trade Calls
07/01/16 07:26 AMInfinity Pharmaceuticals Inc. (INFI) Jumps 5.34% on June 29 - Equities.com
06/30/16 07:31 AMAnalyst Rating Update on Infinity Pharmaceuticals (INFI) - TheFounders Daily
06/29/16 10:08 AMInfinity Regains Duvelisib Rights, Announces Restructuring -
06/29/16 07:29 AMInvestor News: Infinity Pharmaceuticals Inc. (NASDAQ:INFI) under Investigation - GroundReport
06/29/16 07:29 AMBRIEF-Infinity Pharmaceuticals sees workforce restructuring completed by year-end - Reuters
06/29/16 07:29 AMInfinity Pharma cuts 100 jobs after AbbVie deal is terminated - The Boston Globe
06/29/16 07:21 AMCall announcement Infinis plc annual results for the year ending 31 March 2016 £350m 7% Senior Notes due 2019 - [at noodls] - Fax transmission 29 June 2016 Annual Results Announcement £350 million 7% Senior Notes due 2019 Infinis plc (the "Issuer"), an indirectly wholly-owned subsidiary of Infinis Energy Limited (formerly ...
06/28/16 04:35 PMAbbVie Ends Collaboration with Infinity
06/28/16 04:35 PMInfinity Pharma cuts 100 jobs after AbbVie deal is terminated
06/28/16 04:35 PMAbbVie (ABBV) Exercises Right to End Duvelisib Collaboration with Infinity Pharma (INFI)
06/28/16 09:34 AMInfinity Pharmaceuticals : Regains Worldwide Rights To Duvelisib Following Mutual Agreement With AbbVie To End Collaboration
06/28/16 07:22 AMINFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Costs Associated w -
06/28/16 06:11 AMInfinity Regains Worldwide Rights To Duvelisib Following Mutual Agreement With AbbVie To End Collaboration - [at noodls] - CAMBRIDGE, Mass., June 28, 2016 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that AbbVie Inc. has exercised its right to end its collaboration with Infinity to develop ...
06/27/16 04:38 PMShares in Oversold Area: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - Press Telegraph
06/27/16 04:38 PMNoteworthy Stocks: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) , Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) - Street Updates
06/26/16 08:31 AM7 Stocks Under $10 to Trade for Big Post-Brexit Gains -

Social

About Infinity Pharmaceuticals

Infinity Pharmaceuticals logoInfinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: INFI
  • CUSIP: 45665G30
Key Metrics:
  • Previous Close: $1.68
  • 50 Day Moving Average: $1.71
  • 200 Day Moving Average: $4.79
  • P/E Ratio: N/A
  • P/E Growth: -0.01
  • Market Cap: $83.07M
  • Beta: 1.64
  • Current Year EPS Consensus Estimate: $-2.17 EPS
  • Next Year EPS Consensus Estimate: $-1.74 EPS
Additional Links:
Infinity Pharmaceuticals (NASDAQ:INFI) Chart for Friday, July, 29, 2016